Chronic valproic acid treatment triggers increased neuropeptide Y expression and signaling in rat nucleus reticularis thalami

Journal of Neuroscience

Volumn 26, Issue 25, 2006, Pages 6813-6822

  Brill, Julia ^a   Lee, Michelle ^a   Zhao, Sheng ^b   Fernald, Russell D ^b   Huguenard, John R ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Absence seizures; Epilepsy; Hippocampus; nRt; Spike wave discharges; Thalamus

Indexed keywords

CHOLEOCYSTOKININ; NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NEUROPEPTIDE; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR; OCTANOIC ACID; SOMATOSTATIN; UNCLASSIFIED DRUG; VALPROIC ACID; VASOACTIVE INTESTINAL POLYPEPTIDE; ANTICONVULSIVE AGENT; ARGININE; DRUG DERIVATIVE; ENOLASE; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; EPILEPSY; LONG TERM CARE; NONHUMAN; OSCILLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SEDATION; SIGNAL TRANSDUCTION; THALAMUS; ACTION POTENTIAL; ANALYSIS OF VARIANCE; ANIMAL; BIOSYNTHESIS; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; METABOLISM; METHODOLOGY; NEWBORN; PHYSIOLOGY; RADIOIMMUNOASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; THALAMUS MIDLINE NUCLEUS; TIME;

ACTION POTENTIALS; ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; ANTICONVULSANTS; ARGININE; DRUG ADMINISTRATION SCHEDULE; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; MIDLINE THALAMIC NUCLEI; NEUROPEPTIDE Y; PHOSPHOPYRUVATE HYDRATASE; RADIOIMMUNOASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NEUROPEPTIDE Y; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; VALPROIC ACID;

EID: 33745792226     PISSN: 02706474     EISSN: 02706474     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.5320-05.2006     Document Type: Article

References (62)

1. Arias RL, Bowlby MR (2005) Pharmacological characterization of antiepileptic drugs and experimental analgesics on low magnesium-induced hyperexcitability in rat hippocampal slices. Brain Res 1047:233-244.
2. Asghari V, Wang JF, Reiach JS, Young LT (1998) Differential effects of mood stabilizers on Fos/Jun proteins and AP-1 DNA binding activity in human neuroblastoma SH-SY5Y cells. Brain Res Mol Brain Res 58:95-102.
3. Barnea A, Roberts J, Croll SD (2004) Continuous exposure to brain-derived neurotrophic factor is required for persistent activation of TrkB receptor, the ERK signaling pathway, and the induction of neuropeptide Y production in cortical cultures. Brain Res 1020:106-117.
4. Bonini JA, Jones KA, Adham N, Forray C, Artymyshyn R, Durkin MM, Smith KE, Tamm JA, Boteju LW, Lakhlani PP, Raddatz R, Yao WJ, Ogozalek KL, Boyle N, Kouranova EV, Quan Y, Vaysse PJ, Wetzel JM, Branchek TA, Gerald C, Borowsky B (2000) Identification and characterization of two G protein-coupled receptors for neuropeptide FF. J Biol Chem 275:39324-39331.
5. Bourgeois B, Beaumanoir A, Blajev B, de la Cruz N, Despland PA, Egli M, Geudelin B, Kaspar U, Ketz E, Kronauer C (1987) Monotherapy with valproate in primary generalized epilepsies. Epilepsia 28 [Suppl 2]:S8-S11.
6. Burr W, Froescher W, Hoffmann F, Stefan H (1984) Lack of significant correlation between circadian profiles of valproic acid serum levels and epileptiform electroencephalographic activity. Ther Drug Monit 6:179-181.
7. Chadwick DW (1985) Concentration-effect relationships of valproic acid. Clin Pharmacokinet 10:155-163.
8. Chen G, Yuan PX, Jiang YM, Huang LD, Manji HK (1999) Valproate robustly enhances AP-1 mediated gene expression. Brain Res Mol Brain Res 64:52-58.
9. Chronwall BM, DiMaggio DA, Massari VJ, Pickel VM, Ruggiero DA, O'Donohue TL (1985) The anatomy of neuropeptide-Y-containing neurons in rat brain. Neuroscience 15:1159-1181.
10. Cox CL, Huguenard JR, Prince DA (1997) Peptidergic modulation of intrathalamic circuit activity in vitro: actions of cholecystokinin. J Neurosci 17:70-82.
11. Eckstein-Ludwig U, Fei J, Schwarz W (1999) Inhibition of uptake, steady-state currents, and transient charge movements generated by the neuronal GABA transporter by various anticonvulsant drugs. Br J Pharmacol 128:92-102.
12. Einat H, Yuan P, Gould TD, Li J, Du J, Zhang L, Manji HK, Chen G (2003) The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci 23:7311-7316.
13. Ekstrand AJ, Cao R, Bjorndahl M, Nystrom S, Jonsson-Rylander AC, Hassani H, Hallberg B, Nordlander M, Cao Y (2003) Deletion of neuropeptide Y (NPY) 2 receptor in mice results in blockage of NPY-induced angiogenesis and delayed wound healing. Proc Natl Acad Sci USA 100:6033-6038.
14. Erickson JC, Clegg KE, Palmiter RD (1996) Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 381:415-418.
15. Eyer F, Felgenhauer N, Gempel K, Steimer W, Gerbitz KD, Zilker T (2005) Acute valproate poisoning: pharmacokinetics, alteration in fatty acid metabolism, and changes during therapy. J Clin Psychopharmacol 25:376-380.
16. Fraser CM, Sills GJ, Butler E, Thompson GG, Lindsay K, Duncan R, Howatson A, Brodie MJ (1999) Effects of valproate, vigabatrin and tiagabine on GABA uptake into human astrocytes cultured from foetal and adult brain tissue. Epileptic Disord 1:153-157.
17. Furtinger S, Pirker S, Czech T, Baumgartner C, Ransmayr G, Sperk G (2001) Plasticity of Y1 and Y2 receptors and neuropeptide Y fibers in patients with temporal lobe epilepsy. J Neurosci 21:5804-5812.
18. Gean PW, Huang CC, Hung CR, Tsai JJ (1994) Valproic acid suppresses the synaptic response mediated by the NMDA receptors in rat amygdalar slices. Brain Res Bull 33:333-336.
19. Griffith WH, Taylor L (1988) Sodium valproate decreases synaptic potentiation and epileptiform activity in hippocampus. Brain Res 474:155-164.
20. Hansel DE, Eipper BA, Ronnett GV (2001) Neuropeptide Y functions as a neuroproliferative factor. Nature 410:940-944.
21. Hao Y, Creson T, Zhang L, Li P, Du F, Yuan P, Gould TD, Manji HK, Chen G (2004) Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J Neurosci 24:6590-6599.
22. Hassel B, Iversen EG, Gjerstad L, Tauboll E (2001) Up-regulation of hippocampal glutamate transport during chronic treatment with sodium valproate. J Neurochem 77:1285-1292.
23. Henriksen O, Johannessen SI (1982) Clinical and pharmacokinetic observations on sodium valproate-a 5-year follow-up study in 100 children with epilepsy. Acta Neurol Scand 65:504-523.
24. Huguenard JR (1999) Neuronal circuitry of thalamocortical epilepsy and mechanisms of anti-absence drug action. In: Basic mechanisms of the epilepsies (Delgado-Escueta AV, Wilson WA, Olsen RW, Porter RJ, eds), pp 991-999. New York: Lippincott-Raven.
25. Huguenard JR, Prince DA (1994) Intrathalamic rhythmicity studied in vitro: nominal T current modulation causes robust anti-oscillatory effects. J Neurosci 14:5485-5502.
26. B and NMDA receptors contribute to spindle-like oscillations in rat thalamus in vitro. J Neurophysiol 86:1365-1375.
27. Kopp J, Nanobashvili A, Kokaia Z, Lindvall O, Hokfelt T (1999) Differential regulation of mRNAs for neuropeptide Y and its receptor subtypes in widespread areas of the rat limbic system during kindling epileptogenesis. Brain Res Mol Brain Res 72:17-29.
28. Kraiczi H, Karlsson G, Ekman R (1997) Analytical extraction of regulatory peptides from rat lung tissue. Peptides 18:1597-1601.
29. Löscher W (1999) Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol 58:31-59.
30. Löscher W, Honack D (1995) Comparison of anticonvulsant efficacy of valproate during prolonged treatment with one and three daily doses or continuous ("controlled release") administration in a model of generalized seizures in rats. Epilepsia 36:929-937.
31. Löscher W, Nau H (1985) Pharmacological evaluation of various metabolites and analogues of valproic acid. Anticonvulsant and toxic potencies in mice. Neuropharmacology 24:427-435.
32. Luthi A, McCormick DA (1998) H-current: properties of a neuronal and network pacemaker. Neuron 21:9-12.
33. Marksteiner J, Lassmann H, Saria A, Humpel C, Meyer DK, Sperk G (1990) Neuropeptide levels after pentylenetetrazol kindling in the rat. Eur J Neurosci 2:98-103.
34. Meeren HK, Pijn JP, Van Luijtelaar EL, Coenen AM, Lopes da Silva FH (2002) Cortical focus drives widespread corticothalamic networks during spontaneous absence seizures in rats. J Neurosci 22:1480-1495.
35. Mollereau C, Gouarderes C, Dumont Y, Kotani M, Detheux M, Doods H, Parmentier M, Quirion R, Zajac JM (2001) Agonist and antagonist activities on human NPFF(2) receptors of the NPY ligands GR231118 and BIBP3226. Br J Pharmacol 133:1-4.
36. Morland C, Boldingh KA, Iversen EG, Hassel B (2004) Valproate is neuroprotective against malonate toxicity in rat striatum: an association with augmentation of high-affinity glutamate uptake. J Cereb Blood Flow Metab 24:1226-1234.
37. Nadi N, Chen T, Sweet M (2005) Neuropeptide Y may be the final common pathway of valproic acid. Soc Neurosci Abstr 31:94.9.
38. Nadi NS, Swiergosz MJ, Khalid K (1999) Neuropeptide Y inhibits oxygen-induced seizures through the Y2-Y5 receptor. Soc Neurosci Abstr 25:544.3.
39. Nawa H, Bessho Y, Carnahan J, Nakanishi S, Mizuno K (1993) Regulation of neuropeptide expression in cultured cerebral cortical neurons by brain-derived neurotrophic factor. J Neurochem 60:772-775.
40. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276:36734-36741.
41. Reibel S, Larmet Y, Carnahan J, Marescaux C, Depaulis A (2000) Endogenous control of hippocampal epileptogenesis: a molecular cascade involving brain-derived neurotrophic factor and neuropeptide Y. Epilepsia 41 [Suppl 6]:S127-S133.
42. Ren M, Leng Y, Jeong M, Leeds PR, Chuang DM (2004) Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J Neurochem 89:1358-1367.
43. Rowan AJ, Binnie CD, Warfield CA, Meinardi H, Meijer JW (1979) The delayed effect of sodium valproate on the photoconvulsive response in man. Epilepsia 20:61-68.
44. Silva AP, Cavadas C, Grouzmann E (2002) Neuropeptide Y and its receptors as potential therapeutic drug targets. Clin Chim Acta 326:3-25.
45. Sirven JI, Waterhouse E (2003) Management of status epilepticus. Am Fam Physician 68:469-476.
46. Stroud LM, O'Brien TJ, Jupp B, Wallengren C, Morris MJ (2005) Neuropeptide Y suppresses absence seizures in a genetic rat model. Brain Res 1033:151-156.
47. 2+ channels in rat thalamic neurons. J Physiol (Lond) 531:67-79.
48. Sun QQ, Akk G, Huguenard JR, Prince DA (2001b) Differential regulation of GABA release and neuronal excitability mediated by neuropeptide Y1 and Y2 receptors in rat thalamic neurons. J Physiol (Lond) 531:81-94.
49. Sun QQ, Huguenard JR, Prince DA (2002) Somatostatin inhibits thalamic network oscillations in vitro: actions on the GABAergic neurons of the reticular nucleus. J Neurosci 22:5374-5386.
50. Sun QQ, Prince DA, Huguenard JR (2003a) Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide activate hyperpolarization activated cationic current and depolarize thalamocortical neurons in vitro. J Neurosci 23:2751-2758.
51. Sun QQ, Baraban SC, Prince DA, Huguenard JR (2003b) Target-specific neuropeptide Y-ergic synaptic inhibition and its network consequences within the mammalian thalamus. J Neurosci 23:9639-9649.
52. Sundqvist A, Tomson T, Lundkvist B (1998) Valproate as monotherapy for juvenile myoclonic epilepsy: dose-effect study. Ther Drug Monit 20:149-157.
53. Tabb K, Szot P, White SS, Liles LC, Weinshenker D (2004) The ketogenic diet does not alter brain expression of orexigenic neuropeptides. Epilepsy Res 62:35-39.
54. Tu B, Timofeeva O, Jiao Y, Nadler JV (2005) Spontaneous release of neuropeptide Y tonically inhibits recurrent mossy fiber synaptic transmission in epileptic brain. J Neurosci 25:1718-1729.
55. Ueda Y, Willmore LJ (2000) Molecular regulation of glutamate and GABA transporter proteins by valproic acid in rat hippocampus during epileptogenesis. Exp Brain Res 133:334-339.
56. Vezzani A, Sperk G (2004) Overexpression of NPY and Y2 receptors in epileptic brain tissue: an endogenous neuroprotective mechanism in temporal lobe epilepsy? Neuropeptides 38:245-252.
57. Vezzani A, Sperk G, Colmers WF (1999) Neuropeptide Y: emerging evidence for a functional role in Seizure modulation. Trends Neurosci 22:25-30.
58. Whitlow RD, Sacher A, Loo DD, Nelson N, Eskandari S (2003) The anticonvulsant valproate increases the turnover rate of γ-aminobutyric acid transporters. J Biol Chem 278:17716-17726.
59. Wieser HG (1991) Comparison of valproate concentrations in human plasma, CSF and brain tissue after administration of different formulations of valproate or valpromide. Epilepsy Res 9:154-159.
60. Willmore LJ (2003) Divalproex and epilepsy. Psychopharmacol Bull 37 [Suppl 2]:43-53.
61. Wirth MJ, Gorba T, Wahle P (1998) Epigenetic factors regulate the NPY expression in rat cortical neurons. Regul Pept 75-76:283-292.
62. Zhao S, Fernald RD (2005) Comprehensive algorithm for quantitative real-time polymerase chain reaction. J Comput Biol 12:1045-1062.